Real-World Disparities in Molecular Diagnosis of Diffuse Gliomas in Brazil: Insights from LACOG 0619
Clicks: 3
ID: 322354
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
3 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #2 of 40 articles by views in Neuro-Oncology Practice
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Diffuse gliomas in adults are rare aggressive CNS (central nervous system) tumors whose outcomes are strongly influenced by molecular features. In Brazil, data on epidemiology, molecular diagnostics, and survival are scarce, particularly following the WHO CNS 2021 classification. The LACOG 0619 RWD (Real-World Data) addresses this gap by characterizing Brazilian diffuse glioma patients and evaluating diagnostic disparities. Methods This retrospective, multicenter cohort included adults (≥18 years) with histologically confirmed diffuse gliomas from nine centers in Brazil (2010–2019). Reclassification followed WHO CNS 2021 criteria. Completeness of molecular workup was compared between public and private institutions. Results 828 patients were included (median age 52 years, 56.0% male, 57.6% from private centers). Glioblastoma was the most frequent histology (57%). The central finding was a marked disparity in access to molecular diagnostics: IDH (Isocitrate Dehydrogenase), 1p/19q, MGMT (O6-Methylguanine-DNA Methyltransferase), and NGS (Next-Generation Sequencing) testing were far more frequent in private institutions. Although testing rates improved after 2016, <20% of eligible cases underwent IDH sequencing. Survival differed by histology and WHO 2021 criteria, with five-year OS ranging from 20.2% in IDH-wildtype glioblastoma to 90.9% in IDH-mutant grade 2 gliomas (p < 0.001), confirming the prognostic impact of molecular testing. Conclusions LACOG 0619 is the first and largest RWD to assess molecular diagnostic gaps in diffuse gliomas in Brazil. The study reveals profound inequities between public and private healthcare institutions, underscoring the urgent need to expand equitable access to molecular testing as an essential step toward enhancing patient care and ensuring inclusion in precision oncology.
| Reference Key |
openalex_W7170899452
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Camilla Akemi Felizardo Yamada, Marcos Vinícius Calfat Maldaun, Fabiana Spilari Viola, Clarissa Baldotto, Fernando C Maluf, Vanessa Montes Santos, Carolina Fittipaldi Pessôa, Daniela Galvão Barros de Oliveira, Fernanda Maris Peria, Patrícia Pacheco, Danielli Matias, Carolina Pires Vasques, Aknar Calabrich, Gabriela Teixeira de Andrade, Tainá Cabalheiro, Julio Cesar Betiol, Taiane Francieli Rebelatto, Suzana Mária Fleury Malheiros |
| Journal | Neuro-Oncology Practice |
| Year | 2026 |
| DOI |
10.1093/nop/npag072
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.